SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

LYKA LABS

BSE: 500259 28 Jun 2025
Healthcare
₹ 114.2
Lyka Labs Ltd., specializes in Pharmaceuticals within the Healthcare sector.

LYKA LABS - Share Price & Details

Market Cap
₹406.0
High /Low
177.0 / 90.2
Stock P/E
51.2
Book Value
₹29.0
Dividend Yield
0.0
ROCE
9.93
ROE
₹9.24
Face Value
10.0
PEG Ratio
2.86
EVEBITDA
₹22.0
Debt
39.2
CMP / FCF
-463.0
Debt to equity
₹0.38
NP Ann
7.93
High price all time
267.0
Piotroski score
₹5.0
Graham Number
38.1
No. Eq. Shares
3.57
Net CF
₹-4.60
Net profit
7.93
Price to book value
3.92
Interest Coverage
₹5.9
Low price all time
8.15
Industry PE
32.0
Reserves
₹67.9
Free Cash Flow
₹-10.4

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
LYKA LABS LTD.NANANANA406.051.2
MEDICO REMEDIES LIMITED415.9643.41413.030.5239839.5
EVEREST ORGANICS LTD.NANANANA391

Peer Comparison Chart


About LYKA LABS

Lyka Labs Ltd.,, with Security Code 500259, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

How has been the historical performance of the Lyka Labs?

(07 Jun 2025)
Lyka Labs has shown fluctuating financial performance, with net sales increasing from Rs 93.07 crore in March 2023 to Rs 138.50 crore in...
Read more →

Lyka Labs Experiences Valuation Grade Change Amidst Competitive Industry Landscape

(06 Jun 2025)
Lyka Labs, a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, with its current price at 115.80. Over the past year,...
Read more →

Lyka Labs Adjusts Valuation Amid Rising Debt Concerns and Market Position Changes

(04 Jun 2025)
Lyka Labs, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a score adjustment reflecting changes in its financial...
Read more →

Lyka Labs Reports Significant Financial Growth and Improved Valuation Metrics

(30 May 2025)
Lyka Labs has recently experienced a significant evaluation adjustment, reflecting strong financial performance for the quarter ending March 2025.
Read more →

Lyka Labs Reports Strong Financial Growth, Signaling Positive Trends in Pharmaceuticals Sector

(29 May 2025)
Lyka Labs has announced its financial results for the quarter ending March 2025, showcasing significant growth in key metrics. Profit Before Tax reached Rs...
Read more →

Lyka Labs reports consolidated net profit of Rs 2.03 crore in the March 2025 quarter

(27 May 2025)
Sales rise 20.38% to Rs 33.43 crore. Net profit of Lyka Labs reported to Rs 2.03 crore in the quarter ended March 2025 as against net loss of Rs 2.09 crore...
Read more →